Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.

The intracellular androgen metabolism and cell activity in prostate cancer cells with mutated (LNCaP-FGC) or wild-type (VCaP) androgen receptors in the presence of trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, were examined. Trilostane suppressed the intracellular production of androstenedione, testosterone, and dihydrotestosterone from dehydroepiandrosterone in LNCaP-FGC cells. In both LNCaP-FGC and VCaP cell types, the prostate-specific antigen (PSA) levels in media were increased by trilostane alone in a concentration-dependent manner. Both cells pretreated with trilostane showed a dose-dependent decrease in PSA production with bicalutamide (P<0.001). Trilostane should be used with particular concern when treating prostate cancer.

[1]  J. Simard,et al.  DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology , 1995, Annals of the New York Academy of Sciences.

[2]  G. Vinson,et al.  Trilostane in advanced breast cancer , 2006, Expert opinion on pharmacotherapy.

[3]  M. Namer,et al.  Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  F. Labrie,et al.  Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. , 1989, Journal of steroid biochemistry.

[5]  T. Nakada,et al.  Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor). , 1985, Urology.

[6]  J. Simard,et al.  Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. , 2005, Endocrine reviews.

[7]  F. Labrie,et al.  Biosynthesis and Degradation of Androgens in Human Prostatic Cancer Cell Lines , 1990 .

[8]  J. Simard,et al.  Science behind total androgen blockade: from gene to combination therapy. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[9]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.

[10]  J. Geller,et al.  Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH) , 1987, Urological Research.

[11]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[12]  T. Friedlander,et al.  Novel hormonal approaches in prostate cancer , 2009, Current oncology reports.

[13]  G. Hammond.  Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. , 1978, The Journal of endocrinology.

[14]  Kota Takahashi,et al.  The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer , 2004, Clinical Cancer Research.

[15]  G. Vinson,et al.  Non‐competitive steroid inhibition of oestrogen receptor functions , 2002, International journal of cancer.

[16]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[17]  Takashi Suzuki,et al.  Intracrinology of estrogens and androgens in breast carcinoma , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  G. Hortobagyi,et al.  Trilostane with hydrocortisone in treatment of metastatic breast cancer , 1989, Breast Cancer Research and Treatment.

[19]  G. O. Potts,et al.  Trilostane, an orally active inhibitor of steroid biosynthesis , 1978, Steroids.

[20]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[21]  J. Simard,et al.  Role of 17β-Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues , 2000, Trends in Endocrinology & Metabolism.

[22]  G. Vinson,et al.  Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: Up-regulation of oestrogen receptor beta , 2006, The Journal of Steroid Biochemistry and Molecular Biology.